Tag: 2020
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolix Small, expected, non-clinically…
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
Geneva, Switzerland and Boston, MA – Tuesday 14 April, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…
ObsEva SA Announces New Interim Chief Financial Officer
Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva SA: New Date Announcement for AGM
Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva Provides Update Related to COVID-19 Pandemic
Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20,…
ObsEva SA Link to Annual Report 2019
Geneva, Switzerland and Boston, MA – March 5, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva Announces Year End 2019 Financial Results and Business Update
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3…
ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020
Geneva, Switzerland and Boston, MA – February 27, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…